Biotech psychedelics companyHAVN Life Sciences Inc. (OTC:HAVLF)recently closed the initial tranche of its financing pact with innovative fundAlpha Blue Ocean ("ABO"), previously announced on July 21, 2022.

Since its creation in 2017, ABO hasexecuted more than $1.5 billion in financial commitmentsand more than 90 ‎transactions, mostly within the life sciences sector, all around the globe.

Following the current first-tranche closing, HAVN issued to theinvestment fund managed by ABO "Global Corporate Finance Opportunities 17"a total $1,100,000 principal amount of senior unsecured convertible debenture as well as 189,393 common share purchase warrants for net proceeds of approximately $420,000.

Theconvertible debenture may...